Last reviewed · How we verify
CELYVIR
At a glance
| Generic name | CELYVIR |
|---|---|
| Also known as | Bone marrow-derived autologous mesenchymal stem cells infected with ICOVIR5, an oncolytic adenovirus. |
| Sponsor | Hospital Infantil Universitario Niño Jesús, Madrid, Spain |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Repeated Infusion of CELYVIR in Children and Adults With Metastatic and Refractory Tumors. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CELYVIR CI brief — competitive landscape report
- CELYVIR updates RSS · CI watch RSS
- Hospital Infantil Universitario Niño Jesús, Madrid, Spain portfolio CI